Optimal Bayesian-feasible dose escalation for cancer phase I trials

DOI10.1016/S0167-7152(98)00016-9zbMath0903.62064OpenAlexW2063214645MaRDI QIDQ1265963

Shelemyahu Zacks, James S. Babb, André Rogatko

Publication date: 6 January 1999

Published in: Statistics \& Probability Letters (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/s0167-7152(98)00016-9

zbMATH Keywords

constrained optimizationBayesian adaptive procedureBayesian feasible schemecancer phase I clinical trialsdose escalation scheme

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Sequential statistical design (62L05)

Related Items (33)

Patient-specific dose finding in phase I clinical trials ⋮ Optimal sequential designs in phase I studies ⋮ A new design of the continual reassessment method ⋮ Impact of different model structure and prior distribution in continual reassessment method ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ Methodology and application of adaptive and sequential approaches in contemporary clinical trials ⋮ Number of patients per cohort and sample size considerations using dose escalation with overdose control ⋮ Performance Measures in Dose‐Finding Experiments ⋮ Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information ⋮ Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies ⋮ A causal exposure response function with local adjustment for confounding: estimating health effects of exposure to low levels of ambient fine particulate matter ⋮ Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Continual reassessment and related dose-finding designs ⋮ Dose finding with escalation with overdose control (EWOC) in cancer clinical trials ⋮ Approximate dynamic programming and its applications to the design of Phase I cancer trials ⋮ Adaptive Bayesian compound designs for dose finding studies ⋮ Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate ⋮ Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors ⋮ On the consistency of the continual reassessment method with multiple toxicity constraints ⋮ Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs ⋮ Convergence properties of sequential Bayesian \(D\)-optimal designs ⋮ The treatment versus experimentation dilemma in dose finding studies ⋮ Unnamed Item ⋮ Theoretical study of the continual reassessment method ⋮ A conversation with Shelemyahu Zacks ⋮ Incoherent dose-escalation in phase I trials using the escalation with overdose control approach ⋮ Unifying CRM and EWOC designs for phase I cancer clinical trials ⋮ On optimal designs for clinical trials: an updated review ⋮ Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials ⋮ Optimal designs for dose-escalation trials and individual allocations in cohorts

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Design and Analysis of Phase I Clinical Trials
• Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response Curve
• Unnamed Item
• Unnamed Item
• Unnamed Item

This page was built for publication: Optimal Bayesian-feasible dose escalation for cancer phase I trials